Relay Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.42, Implies 52% Upside
Relay Therapeutics, Inc.'s average stock price target was reduced from $27.58 to $27.42 by 12 analysts, with a range of $20 to $32. This implies a 52% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 13 analysts.
How this was made
The 30-second read
Why it matters
The price‑target reduction reflects slightly weaker consensus expectations, which may prompt short‑term selling but leaves room for upside if upcoming catalysts materialize.
Market read
A modest analyst target cut provides a short‑term trading signal for RLAY, with limited broader market effect.
What to watch
Potential upcoming clinical data or partnership announcements could quickly reverse the modest downgrade.
Background
Relay Therapeutics is a biotech firm developing precision medicines; analyst coverage is limited but active.
Ticker impact
Analysts cut Relay Therapeutics' average 12‑month price target to $27.42, down from $27.58, implying 52% upside from the latest close.
downward pressure as the market prices in the lower target
A price‑target cut, even small, often leads to short‑term sell‑side activity; the implied upside remains large but the downgrade reduces enthusiasm.
Market effects
May slightly temper enthusiasm for biotech small‑caps as analysts tighten expectations.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; only relevant to traders tracking Relay Therapeutics.
Counterpoint
Despite the target cut, the 52% upside still suggests a buying opportunity if the market overreacts.
Key entities
- CompanyRelay Therapeutics, Inc.
Biotech firm focused on precision medicine.
- Data ProviderFactSet
Source of the analyst consensus data.
